News >

Ramalingam Reflects on Recent Advances in SCLC

Angelica Welch
Published: Monday, Jul 16, 2018

Suresh S. Ramalingam, MD

Suresh S. Ramalingam, MD
The small cell lung cancer (SCLC) landscape is experiencing a wave of new clinical trials, many of which are proving the activity of novel targeted agents and immunotherapy. Suresh A. Ramalingam, MD, explained that the field is anxiously awaiting phase III data to confirm the promise that these agents have shown so far.

, Ramalingam, deputy director of Winship Cancer Institute of Emory University, reflected on recent data and what is on the horizon for SCLC.

OncLive: What are your thoughts on the phase II data with lurbinectedin?

Ramalingam: It was a small study of about 60 patients, but it showed activity in both the platinum-sensitive and platinum-refractory patients. The median PFS was very promising. I came out of [the 2018 ASCO Annual Meeting] thinking it could be something helpful for our patients. There is a phase III clinical trial with lurbinectedin that is currently underway, and this only makes it more exciting to see what the results of that phase III trial will be. [The ATLANTIS study] is a randomized phase III trial that has been ongoing for about 1.5 years.

In light of the results presented at the 2018 ASCO Annual Meeting, do you have any further thoughts on Rova-T?

The presentation at the 2018 ASCO Annual Meeting showed a low response rate with Rova-T, even in the biomarker-positive patients. That is lower than the 40% response rate reported from the first cohort of patients. In the broader experience, it looks like the drug may not be as active as we had previously thought.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication